November - 2018

MECFA Blog

New Test of Mucus Properties May Help with Coughing and Airway Clearance in CF

A new test was able to assess various properties of the mucus that accumulates in the lungs of people with cystic fibrosis and other...

Avycaz May Be Effective for Multidrug-resistant P. aeruginosa Infections in CF Patients, Study Sugge

Antibacterial Avycaz (ceftazidime-avibactam) showed significant in vitroefficacy against multidrug-resistant Pseudomonas aeruginosa...

Ultrasound Predicts Advanced Liver Disease in CF Patients, According to Clinical Trial Data

Ultrasound may predict liver disease in young cystic fibrosis (CF) patients, according to the results of a clinical trial. Researchers...

New cystic fibrosis drugs significantly improve lung function

A triple drug combination for treating the underlying cause of cystic fibrosis is currently under study. The preliminary results show a...

Law Student returned to life with lung transplantation

Law student came back to life with lung transplantation, 20 years of law student struggles with genetic disease ISTANBUL – For many...

The Bittersweet Downside of CFTR Modulators

I’ve been on Orkambi (lumacaftor/ivacaftor), a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, for just over three...

#NACFC2018 – RPL554 Shows Promising Results in CF Studies

Positive data from preclinical and Phase 2a studies evaluating the investigational cystic fibrosis (CF) treatment RPL554 were presented...

Worse CF Lung Outcomes Linked with Mutations Causing Iron Overload Disorder, Study Finds

Patients with cystic fibrosis (CF) who carry certain mutations in the HFE gene, which are also behind an iron overload disorder, have...

Cystic Fibrosis Lung Function Improved With Triple Therapy

Patients with cystic fibrosis with either 1 or 2 Phe508del alleles who were treated with a drug combination of VX-659, tezacaftor, and...

Mucus, cough and chronic lung disease: New discoveries

As a cold ends, a severe mucus cough starts. Sound familiar? Two studies now give explanations: First, crucial mechanisms of the mucus in...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p